Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Aim: To investigate the efficacy of systemic corticosteroids in treatment for Post-COVID-19
Interstitial Lung Disease.
Method: Method: In this multi-centre, prospective, randomised controlled open label clinical
trial, patients are divided into two arms: standard treatment arm and standard plus systemic
corticosteroid arm. After four weeks, clinical response will being assessed as primary
outcome.